Conditionally replicating recombinant cells, compositions and vaccines having the cells, and methods of using the cells, are provided.

Fibronectin type III domains (FN3) that bind to serum albumin, related polynucleotides capable of encoding serum albumin-binding FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Fibronectin type III domains (FN3) that bind to serum albumin, related polynucleotides capable of encoding serum albumin-binding FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Provided herein are compositions and methods for modulating induction of quorum sensing in bacterial cells. For example, provided herein is a method of inducing method of inducing quorum sensing, where the method includes: culturing a bacterial strain, wherein the bacterial strain comprises a first nucleic acid sequence encoding a first activator polypeptide, wherein expression of the first activator polypeptide produces a quorum sensing molecule precursor; a second nucleic acid sequence encoding a second activator polypeptide, wherein expression of the second activator polypeptide produces a quorum sensing; a third nucleic acid sequence encoding a third activator polypeptide that is capable of activating the quorum sensing system; a fourth nucleic acid sequence encoding a gene of interest, and contacting the bacterial strain with an inducer molecule; and converting the inducer molecule into a quorum sensing molecule, thereby allowing induction of quorum sensing.

There is provided a mutant KLF protein that can induce reprogramming of a somatic cell at a higher efficiency than a KLF protein having a natural amino acid sequence. There is also provided a method for efficiently producing an iPS cell by using the mutant KLF protein. There is provided a mutant KLF protein having an amino acid substitution, or a peptide fragment thereof containing the amino acid substitution.

Provided are a tumor immune enhancer, a pharmaceutical composition thereof, and a preparation method therefor. The enhancer comprises one or more polypeptides using sequences shown in SEQ ID NOs.: 1-9 as core structures, and can be used for preparing tumor vaccines.

Provided are a tumor immune enhancer, a pharmaceutical composition thereof, and a preparation method therefor. The enhancer comprises one or more polypeptides using sequences shown in SEQ ID NOs.: 1-9 as core structures, and can be used for preparing tumor vaccines.

The present invention relates to a monomeric polypeptide including a single subunit comprising the active site of a [NiFe]-hydrogenase-like protein, said monomeric polypeptide having hydrogenase activity.

The present invention relates to a monomeric polypeptide including a single subunit comprising the active site of a [NiFe]-hydrogenase-like protein, said monomeric polypeptide having hydrogenase activity.

Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These Anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.